Crossmark

Review of SGLT2i for the Treatment of Renal Complications: Experience in Patients with and Without T2D

Published Online: 2022-06-15

Published Print: 2022-07

Authors

González-Albarrán, Olga

Morales, Cristóbal

Pérez-Maraver, Manuel

Aparicio-Sánchez, José Juan

Simó, Rafael
Funding

Funding for this research was provided by:

AstraZeneca
License Information

Text and Data Mining valid from 2022-06-15

Version of Record valid from 2022-06-15
More Information

Article History

Received: 3 March 2022

Accepted: 13 May 2022

First Online: 15 June 2022

Document is current